Flavonoid guide
Flavonoids

Luteolin

Luteolin is a plant-derived flavone found in herbs, vegetables, and teas. It has demonstrated anti-inflammatory and antioxidant activity in cell and animal studies, with a small number of human studies suggesting modest symptom modulation in allergic and neuroinflammatory conditions.

3',4',5,7-tetrahydroxyflavone
Luteolin aglycone
Luteolin glycosides
Luteoline

This guide covers all common forms and variations of luteolin in one place. Use the sections below to find the form that fits your situation.

How it works in the body

Luteolin acts on multiple cellular signaling pathways linked to inflammation and oxidative stress. It inhibits NF-κB activation, which reduces expression of pro-inflammatory enzymes (COX-2, iNOS) and cytokines (TNF-α, IL-6). Luteolin also modulates MAP kinase pathways and suppresses mast cell mediator release, which underlies some reported effects on allergy and neuroinflammation.

In parallel, luteolin activates Nrf2-driven antioxidant-response elements and scavenges reactive oxygen species in vitro. It inhibits several CYP enzymes and P-glycoprotein in experimental systems, creating potential for pharmacokinetic interactions with co-administered drugs. These pleiotropic actions explain activity across immune, neural, and vascular cell types but complicate translation from cell and animal models to humans, where achievable plasma concentrations are substantially lower than those used in most in vitro work.

Luteolin molecular structure
2D molecular structure from PubChem, National Library of Medicine.

Body systems

Immune function
Nervous system
Cardiovascular system
Respiratory / Allergy

Associated molecules

NF-κB
Nrf2
COX-2
TNF-α

Track it lightly

If you decide to track luteolin, start with dietary sources or a conservative supplement dose and record symptom changes and any side effects over several weeks to evaluate personal benefit.

Trying this? Start tracking it here.

Background

Luteolin has been studied in botanical chemistry and pharmacology for decades. Traditional uses of luteolin-rich plants — chamomile, thyme, celery — include anti-inflammatory and antispasmodic applications. Interest intensified as molecular tools revealed luteolin's ability to inhibit inflammatory transcription factors and modulate oxidative stress. Over the past 20 years most mechanistic work has used preclinical models, with only a small number of human studies attempting to test clinical effects.

Evidence snapshot

Most evidence for luteolin comes from in vitro and animal studies demonstrating anti-inflammatory, antioxidant, and neuroprotective mechanisms. These studies show luteolin inhibits inflammatory transcription factors (e.g., NF-κB), reduces pro-inflammatory cytokines (TNF-α, IL-6), and activates antioxidant responses (Nrf2).

Human data are limited. Small clinical reports and open-label studies have used luteolin-containing supplements — often combined with quercetin — for conditions such as allergic disorders and autism-spectrum disorder. Results are preliminary and confounded by multi-ingredient formulations and small sample sizes.

Bioavailability and formulation matter: luteolin occurs in foods mainly as glycosides, which have different absorption profiles than the aglycone. Effective concentrations in many in vitro studies exceed achievable plasma levels after oral intake, making clinical translation uncertain.

Safety data in humans are sparse. Dietary luteolin appears well tolerated. High-dose or long-term safety has not been established in rigorous randomized trials, and caution is warranted for people taking medications metabolized by CYP enzymes or anticoagulants.

Bioavailability and formulations

Luteolin in foods is predominantly present as glycosides; intestinal enzymes and gut microbiota cleave glycosides to release the aglycone before absorption. Absorption of free luteolin is modest and extensive phase II metabolism (glucuronidation, sulfation) yields conjugates that circulate at higher concentrations than the parent aglycone. Plasma concentrations achieved after typical oral doses are often below the concentrations used in in vitro studies, limiting direct extrapolation of mechanistic findings. Several supplement manufacturers use phospholipid complexes (phytosomes) or other delivery systems aiming to increase absorption, but head-to-head human pharmacokinetic comparisons between formulations remain limited.

Populations studied

Most human data come from small open-label studies or case series using luteolin combined with other flavonoids (most often quercetin) in children with neurodevelopmental disorders or in allergy cohorts. The bulk of mechanistic evidence comes from cell culture and animal models. There are no large randomized controlled trials in adults for any specific indication, and special populations — including pregnant or lactating individuals and those on polypharmacy — have not been adequately studied.

Long-term safety and toxicity

Long-term safety data for supplemental luteolin in humans are lacking. Animal studies indicate low acute toxicity, though some high-dose animal studies have identified organ-specific effects. Because luteolin inhibits drug-metabolizing enzymes in vitro, interaction potential exists for people on medications with narrow therapeutic windows. Until more human safety data are available, long-term high-dose supplementation should be discussed with a healthcare provider.

Research gaps and uncertainties

Key gaps include limited human pharmacokinetic data across formulations, a near-absence of randomized controlled trials for specific clinical indications, and uncertain clinical significance of in vitro CYP inhibition. Well-designed human trials are needed to define effective doses, optimal formulations, and safety profiles — particularly for chronic use and in people taking concurrent medications.

Compound variations

Luteolin (aglycone)

Luteolin

The sugar-free form used in most supplements and experimental studies. Absorption is limited and the compound undergoes extensive phase II metabolism after oral intake.

Common use case

Standardized supplement formulations where the dose of pure luteolin is specified.

Dosage note

Small human reports have used approximately 50–200 mg/day; bioavailability is limited compared with some glycoside or complexed forms.

Luteolin-7-O-glucoside (glycoside)

Luteolin

A common plant glycoside form of luteolin present in many foods and herbs. Requires gut metabolism for conversion to the absorbable aglycone and may have a different absorption profile.

Common use case

Dietary intake from herbs and foods; botanical extracts standardized to total luteolin equivalents.

Dosage note

Supplements typically report total luteolin equivalents rather than glycoside content separately.

Luteolin + Quercetin combinations

Luteolin

Supplement blends pairing luteolin with quercetin or other flavonoids. Most published small human studies have used combination products, which complicates attributing effects to luteolin alone.

Common use case

Multi-flavonoid modulation of inflammatory responses; check labeling for the specific luteolin content.

Dosage note

In small studies, luteolin content in combination products has ranged roughly 60–200 mg/day. Verify individual ingredient amounts on the product label.

Luteolin phytosome / enhanced-bioavailability forms

Luteolin

Formulations complexing luteolin with phospholipids or other carriers aim to increase absorption and plasma exposure. Comparative human pharmacokinetic data versus standard luteolin are limited.

Common use case

Users seeking higher bioavailability from supplements.

Dosage note

Follow manufacturer dosing. No standardized conversion to aglycone equivalent has been validated in clinical trials.

Dosage and best practices

Dosage principles

  • Dietary intake: typical food-derived intakes are low (often under 5 mg/day); therapeutic studies use substantially higher amounts from supplements.
  • Small clinical reports and formulations have used luteolin in the range of 60–200 mg/day as a supplement, often combined with quercetin. No standardized clinical dose has been established.
  • Oral bioavailability is limited. Divided dosing (e.g., two doses totaling 100–200 mg/day) or use of enhanced-bioavailability forms (glycosides, phytosomes) has been employed in some trials to raise plasma exposure.

Best practices

  • Prefer whole-food sources — herbs, vegetables, chamomile tea — for low-dose dietary luteolin rather than high-dose supplementation unless guided by a clinician.
  • If using supplements, select formulations that specify luteolin content; start at a conservative dose (50–100 mg/day) and assess response over several weeks.
  • Monitor for drug interactions if you take medications metabolized by CYP enzymes or anticoagulants. Consult a clinician before starting luteolin supplements.

Literature and references

Common questions

Will luteolin treat allergies or asthma?

Luteolin reduces inflammatory mediator release in cell and animal models of allergic inflammation, and small human reports suggest symptom reduction. There is not enough clinical trial evidence to consider luteolin a proven treatment for allergies or asthma. Continue prescribed therapies unless advised otherwise by a clinician.

Is luteolin safe to take every day?

Dietary luteolin from foods is generally safe. Long-term safety of concentrated supplemental luteolin is not well established in humans. Start with a conservative dose and consult your healthcare provider, especially if you take medications that could interact.

What is the difference between luteolin aglycone and luteolin glycosides?

Glycosides are luteolin molecules bound to sugar residues; they are the predominant form in plants and require gut metabolism before absorption. The aglycone is the sugar-free form used in many supplements. The two forms differ in absorption rate and gut metabolism, which affects bioavailability.

Can luteolin interact with my medications?

In vitro studies show luteolin inhibits several CYP enzymes and drug transporters, so interactions are plausible. People taking medications with narrow therapeutic windows (e.g., warfarin) or that are major CYP3A4 substrates should consult a clinician before using luteolin supplements.

How long before I might notice effects?

Expected timing is uncertain given the limited and often combination-product human evidence. Small reports of allergy or neuroinflammatory symptoms describe changes over weeks. Tracking symptoms daily or weekly for at least 4–8 weeks provides a reasonable personal assessment window.

Related guides